Eczema (Atopic Dermatitis) and Food Allergy

Deep Dive

From a western clinical standpoint, eczema and food allergy are related by shared atopic biology, most prominent in infancy. A dysfunctional epi... From a western clinical standpoint, eczema and food allergy are related by shared atopic biology, most prominent in infancy. A dysfunctional epidermal barrier—amplified by filaggrin variants—permits allergens to penetrate inflamed skin. In that milieu, dendritic cells present food proteins to a Th2‑biased immune system, encouraging class‑switching to IgE. Epidemiology aligns with this model: infants with moderate‑to‑severe eczema are far more likely to have egg or peanut allergy than peers without eczema in population‑based cohorts. Environmental cutaneous exposure, such as household peanut dust or topical products containing food proteins, further elevates risk, especially when barrier impairment is pronounced. Clinically, the overlap is nuanced. IgE‑mediated food allergy typically causes rapid hives, vomiting, wheeze, or anaphylaxis after ingestion. By contrast, food‑exacerbated eczema features delayed or subacute skin worsening; non‑IgE pathways may be involved, and objective confirmation is challenging. Because skin prick testing and serum specific IgE detect sensitization rather than clinical allergy, they have modest positive predictive value in eczema populations. Over‑reliance on tests can lead to unnecessary food avoidance with growth and feeding consequences. Accordingly, guidelines emphasize careful history, targeted testing, and supervised oral food challenges as the diagnostic gold standard when uncertainty remains. Management integrates skin and allergy care. First, optimize eczema with emollients, topical anti‑inflammatories, and measures to reduce Staphylococcus aureus. For confirmed IgE‑mediated food allergy, strict avoidance and anaphylaxis preparedness are essential; oral immunotherapy may be considered in specialist settings. Prevention strategies are a major success: early peanut introduction for infants with eczema reduces later peanut allergy, with data for egg emerging. Biologics underscore shared mechanisms: omalizumab now has evidence and approval for food allergy and may modestly benefit eczema in select patients, while dupilumab powerfully treats eczema and shows early promise as an adjunct in food desensitization. Throughout, nutrition support from a registered dietitian helps avoid the harms of unnecessary restriction while maintaining growth and developmental feeding skills.